menu
    • menu
    [{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Elixirgen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elixirgen Therapeutics \/ Elixirgen Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Elixirgen Therapeutics"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Fujita Health University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixirgen Therapeutics \/ Fujita Health University","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Fujita Health University"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EXG-5003","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EXG34217","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"EXG-001","moa":"||ZSCAN4","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"EXG-34217","moa":"ZSCAN4","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EXG-34217","moa":"ZSCAN4","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EXG-34217","moa":"ZSCAN4","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Elixirgen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Hitachi Global Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"EXG-34217","moa":"ZSCAN4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Taisho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elixirgen Therapeutics \/ Elixirgen Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Elixirgen Therapeutics \/ Elixirgen Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Elixirgen Therapeutics

    Menu

    Elixirgen Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elixirgen Gets FDA Orphan Drug Designation for Telomere Disorders

                            Details : EXG-34217 is a dose of autologous CD34+ hematopoietic stem cells (HSCs) that is being investigated for the treatment of telomere biology disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elixirgen's EXG-34217 Gets FDA RMAT for Treating Telomere Biology Disorders

                            Details : EXG-34217 is a dose of autologous CD34+ hematopoietic stem cells (HSCs) that is being investigated for the treatment of telomere biology disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elixirgen Receives Rare Pediatric Designation for EXG-34217 in Dyskeratosis Congenita

                            Details : EXG-001, a non-integrating, non-transmissible, temperature-sensitive Sendai virus vector encoding human ZSCAN4, being evaluated for dyskeratosis congenita and related telomere biology disorders.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 25, 2024

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-5003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-...

                            Details : EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology. The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 16, 2023

                            Lead Product(s) : EXG-5003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG34217

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rollover Study From EXG-US-01

                            Details : EXG34217 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Telomere Biology Disorders-associated with Bone Marrow Failure.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : EXG34217

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Hitachi Global Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Developme...

                            Details : Elixirgen Therapeutics is currently conducting a Phase 1/2 trial of EXG-34217, an autologous cell therapy to treat patients with telomere biology disorders with bone marrow failure. The collaboration with Hitachi would result in the development of Micro ...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 26, 2023

                            Lead Product(s) : EXG-34217

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Hitachi Global Life Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-34217,EXG-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elixirgen Therapeutics to Present New Data Showing Successful Ex Vivo Telomere Elongation with EXG-34217 in a ...

                            Details : EXG-34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure that uses Elixirgen Therapeutics’ proprietary ZSCAN4 technology to extend the telomeres of the patients.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : EXG-34217,EXG-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Recipient : Taisho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases

                            Details : The partnership will leverage Elixirgen's proprietary ZSCAN4 therapy platform to advance treatments of aging-associated diseases. Elixirgen Therapeutics is currently performing a Phase I/II clinical trial using its ZSCAN4 therapy platform in disorders wi...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Recipient : Taisho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-5003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Fujita Health University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity of EXG-5003

                            Details : EXG-5003 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 28, 2021

                            Lead Product(s) : EXG-5003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Fujita Health University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Elixirgen Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXG-5003

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Fujita Health University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elixirgen Therapeutics Planning to Begin Phase I/II Clinical Trials of Its Covid-19 Vaccine Candidate Exg-5003...

                            Details : EXG-5003 is a temperature-sensitive self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein. EXG-5003 was optimized for intradermal injection with potential dose-sparing and safety benefits.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 01, 2020

                            Lead Product(s) : EXG-5003

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Fujita Health University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth